<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37148484</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1926</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical pharmacokinetics</Title><ISOAbbreviation>Clin Pharmacokinet</ISOAbbreviation></Journal><ArticleTitle>Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.</ArticleTitle><Pagination><StartPage>655</StartPage><EndPage>671</EndPage><MedlinePgn>655-671</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40262-023-01238-2</ELocationID><Abstract><AbstractText>The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population-pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population-pharmacokinetics and exposure-response analyses are reviewed.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Weifeng</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8261-8116</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, R&amp;D, AstraZeneca, Gaithersburg, MD, USA. Weifeng.Tang@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tummala</LastName><ForeName>Raj</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5506-4445</Identifier><AffiliationInfo><Affiliation>Clinical Development, Late Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almquist</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4745-9332</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, R&amp;D, AstraZeneca, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3451-3413</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, R&amp;D, AstraZeneca, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Wendy I</ForeName><Initials>WI</Initials><Identifier Source="ORCID">0000-0002-3286-0043</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulton</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology, Clinical Pharmacology &amp; Safety Sciences, R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Clin Pharmacokinet</MedlineTA><NlmUniqueID>7606849</NlmUniqueID><ISSNLinking>0312-5963</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>38RL9AE51Q</RegistryNumber><NameOfSubstance UI="C582345">anifrolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors are employed by AstraZeneca.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>14</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37148484</ArticleId><ArticleId IdType="pmc">PMC10182164</ArticleId><ArticleId IdType="doi">10.1007/s40262-023-01238-2</ArticleId><ArticleId IdType="pii">10.1007/s40262-023-01238-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford) 2017;56(10):1662&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">28122959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus&#x2013;focus on targeting interferon-alpha. Clin Immunol. 2012;143(3):210&#x2013;221. doi: 10.1016/j.clim.2012.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2012.03.005</ArticleId><ArticleId IdType="pmc">PMC3358492</ArticleId><ArticleId IdType="pubmed">22525889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy M, Tummala R, Streicher K, Noqueria da Costa A, Brohawn P. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci. 2021;22(20):11286. doi: 10.3390/ijms222011286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011286</ArticleId><ArticleId IdType="pmc">PMC8540355</ArticleId><ArticleId IdType="pubmed">34681945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, R&#xf6;nnblom L. Role of interferons in SLE. Best Pract Res Clin Rheumatol. 2017;31(3):415&#x2013;428. doi: 10.1016/j.berh.2017.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2017.10.003</ArticleId><ArticleId IdType="pubmed">29224681</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-&#x3b1; monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909&#x2013;1916. doi: 10.1136/annrheumdis-2015-208562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208562</ArticleId><ArticleId IdType="pmc">PMC5099191</ArticleId><ArticleId IdType="pubmed">27009916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9(9):664&#x2013;671. doi: 10.1191/096120300674499064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300674499064</ArticleId><ArticleId IdType="pubmed">11199920</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610&#x2013;2615. doi: 10.1073/pnas.0337679100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491&#x2013;1503. doi: 10.1002/art.21031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21031</ArticleId><ArticleId IdType="pubmed">15880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Sinicato NA, Peli&#xe7;ari KO, Marini R, Lavras Costallat LT, Appenzeller S. Clinical and serological manifestations associated with interferon-&#x3b1; levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) 2012;67(2):157&#x2013;162. doi: 10.6061/clinics/2012(02)11.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2012(02)11</ArticleId><ArticleId IdType="pmc">PMC3275113</ArticleId><ArticleId IdType="pubmed">22358241</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC., Jr Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64(12):1692&#x2013;1697. doi: 10.1136/ard.2004.033753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.033753</ArticleId><ArticleId IdType="pmc">PMC1755300</ArticleId><ArticleId IdType="pubmed">15843451</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951&#x2013;2962. doi: 10.1002/art.22044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22044</ArticleId><ArticleId IdType="pubmed">16947629</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Higgs BW, Richman L, White B, Jallal B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN&#x3b1; antibody, in systemic lupus erythematosus. Arthritis Res Ther. 2010;12 Suppl 1(Suppl 1):S6. doi: 10.1186/ar2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2887</ArticleId><ArticleId IdType="pmc">PMC2991779</ArticleId><ArticleId IdType="pubmed">20392292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy WP, Maciuca R, Wolslegel K, Tew W, Abbas AR, Chaivorapol C, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med. 2015;2(1):e000080. doi: 10.1136/lupus-2014-000080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000080</ArticleId><ArticleId IdType="pmc">PMC4379884</ArticleId><ArticleId IdType="pubmed">25861459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman RW, Merrill JT, Alarc&#xf3;n-Riquelme MM, Petri M, Dow ER, Nantz E, et al. Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two Phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol. 2017;69(3):643&#x2013;654. doi: 10.1002/art.39950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39950</ArticleId><ArticleId IdType="pmc">PMC6585752</ArticleId><ArticleId IdType="pubmed">27723281</ArticleId></ArticleIdList></Reference><Reference><Citation>Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000261</ArticleId><ArticleId IdType="pmc">PMC5890856</ArticleId><ArticleId IdType="pubmed">29644082</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca. Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus [press release]. August 2, 2021 [cited January 11, 2022]; https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html. Accessed 11 Jan 2022.</Citation></Reference><Reference><Citation>AstraZeneca. Saphnelo recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus [press release]. December 20, 2021 [cited January 11, 2022]; https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-recommended-for-eu-approval-for-sle.html. Accessed 11 Jan 2022.</Citation></Reference><Reference><Citation>AstraZeneca. Saphnelo approved in Japan for systemic lupus erythematosus [press release]. September 28, 2021 [cited January 11, 2022]; https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html. Accessed 11 Jan 2022.</Citation></Reference><Reference><Citation>AstraZeneca. Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus. February 16, 2022 [cited March 8, 2022]; https://www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html. Accessed 8 Mar 2022.</Citation></Reference><Reference><Citation>Bruce I, Nami A, Schwetje E, Pierson M, Chia Y, Kuruvilla D, et al. PK/PD, safety and exploratory efficacy of subcutaneous anifrolumab in SLE: A Phase-II study in interferon type I high patients with active skin disease [Abstract 2563]. Annual Meeting of the American College of Rheumatology; November 8-13, 2019; Atlanta, Georgia.</Citation></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376&#x2013;386. doi: 10.1002/art.39962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, Phase 3 trial. Lancet Rheumatol. 2019;1(4):e208&#x2013;e219. doi: 10.1016/S2665-9913(19)30076-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca Pharmaceuticals LP. SAPHNELO (anifrolumab-fnia) injection [full prescribing information]. July 2021 [cited 2022 January 19,]; https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c_viewable_rendition__v.pdf. Accessed 19 Jan 2022.</Citation></Reference><Reference><Citation>Wilmes S, Beutel O, Li Z, Francois-Newton V, Richter CP, Janning D, et al. Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling. J Cell Biol. 2015;209(4):579&#x2013;593. doi: 10.1083/jcb.201412049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201412049</ArticleId><ArticleId IdType="pmc">PMC4442803</ArticleId><ArticleId IdType="pubmed">26008745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanin N, Viaris Lesegno C, Lamaze C, Blouin CM. Interferon receptor trafficking and signaling: Journey to the cross roads. Front Immunol. 2021;11:615603. doi: 10.3389/fimmu.2020.615603.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.615603</ArticleId><ArticleId IdType="pmc">PMC7855707</ArticleId><ArticleId IdType="pubmed">33552080</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-&#x3b1; receptor 1 antibody. MAbs. 2015;7(2):428&#x2013;439. doi: 10.1080/19420862.2015.1007810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2015.1007810</ArticleId><ArticleId IdType="pmc">PMC4622752</ArticleId><ArticleId IdType="pubmed">25606664</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkiel S, Barlev AN, Atisha-Fregoso Y, Suurmond J, Diamond B. Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol. 2018;9:427. doi: 10.3389/fimmu.2018.00427.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00427</ArticleId><ArticleId IdType="pmc">PMC5845388</ArticleId><ArticleId IdType="pubmed">29556239</ArticleId></ArticleIdList></Reference><Reference><Citation>Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008;64(Pt 6):700&#x2013;704. doi: 10.1107/S0907444908007877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444908007877</ArticleId><ArticleId IdType="pmc">PMC2467532</ArticleId><ArticleId IdType="pubmed">18560159</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Higgs BW, Morehouse C, de Los RM, Trigona W, Brohawn P, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-&#x3b1; monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics. 2009;17(2009):374312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950308</ArticleId><ArticleId IdType="pubmed">20948567</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, et al. Dose-escalation of human anti-interferon-&#x3b1; receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a Phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16(1):R57. doi: 10.1186/ar4492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4492</ArticleId><ArticleId IdType="pmc">PMC3978926</ArticleId><ArticleId IdType="pubmed">24559157</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol. 2021;31(1):1&#x2013;12. doi: 10.1080/14397595.2020.1812201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1812201</ArticleId><ArticleId IdType="pubmed">32814461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, Phase 2, open-label study. Mod Rheumatol. 2020;30(1):101&#x2013;108. doi: 10.1080/14397595.2019.1583833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2019.1583833</ArticleId><ArticleId IdType="pubmed">30793642</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496&#x2013;506. doi: 10.1136/annrheumdis-2021-221478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a Phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816&#x2013;825. doi: 10.1002/art.41598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41598</ArticleId><ArticleId IdType="pmc">PMC8252065</ArticleId><ArticleId IdType="pubmed">33225631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala R, Rouse T, Berglind A, Santiago L. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5(1):e000252. doi: 10.1136/lupus-2017-000252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000252</ArticleId><ArticleId IdType="pmc">PMC5890854</ArticleId><ArticleId IdType="pubmed">29644080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576&#x2013;588. doi: 10.1002/psp4.12224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12224</ArticleId><ArticleId IdType="pmc">PMC5613179</ArticleId><ArticleId IdType="pubmed">28653357</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzenstadler J, Chen J, Park A, Neuner R, Thompson A, He L, et al. Impact of proteinuria on the clearance of monoclonal antibodies: Potential clinical implications [Abstract 0868]. Arthritis Rheumatol. 2020;72 (Suppl 10). https://acrabstracts.org/abstract/impact-of-proteinuria-on-the-clearance-of-monoclonal-antibodies-potential-clinical-implications/. Accessed: 11 Apr 2023.</Citation></Reference><Reference><Citation>Almquist J, Kuruvilla D, Mai T, Tummala R, White WI, Tang W, et al. Nonlinear population pharmacokinetics of anifrolumab in healthy volunteers and patients with systemic lupus erythematosus. J Clin Pharmacol. 2022;62(9):1106&#x2013;1120. doi: 10.1002/jcph.2055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2055</ArticleId><ArticleId IdType="pmc">PMC9540432</ArticleId><ArticleId IdType="pubmed">35383948</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales E, Galindo M, Trujillo H, Praga M. Update on lupus nephritis: looking for a new vision. Nephron. 2021;145(1):1&#x2013;13. doi: 10.1159/000511268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000511268</ArticleId><ArticleId IdType="pubmed">33147587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-&#x3b1; receptor antibody. Drug Des Devel Ther. 2013;93(6):483&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia YL, Santiago L, Wang B, Kuruvilla D, Wang S, Tummala R, et al. Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2021;60(12):5854&#x2013;5862. doi: 10.1093/rheumatology/keab176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab176</ArticleId><ArticleId IdType="pubmed">33629110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia YL, Tummala R, Mai TH, Rouse T, Streicher K, White WI, et al. Relationship between anifrolumab pharmacokinetics, pharmacodynamics, and efficacy in patients with moderate to severe systemic lupus erythematosus. J Clin Pharmacol. 2022;62(9):1094&#x2013;1105. doi: 10.1002/jcph.2054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2054</ArticleId><ArticleId IdType="pmc">PMC9545691</ArticleId><ArticleId IdType="pubmed">35352835</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493&#x2013;507. doi: 10.2165/11531280-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11531280-000000000-00000</ArticleId><ArticleId IdType="pubmed">20608753</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633&#x2013;659. doi: 10.2165/11535960-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11535960-000000000-00000</ArticleId><ArticleId IdType="pubmed">20818831</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6257383</ArticleId><ArticleId IdType="pubmed">30538817</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey KA, Smith MA, Sinibaldi D, Seto NL, Playford MP, Wang X, et al. Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(3):459&#x2013;471. doi: 10.1002/art.41518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41518</ArticleId><ArticleId IdType="pubmed">32909675</ArticleId></ArticleIdList></Reference><Reference><Citation>Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-&#x3b1; monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet. 2013;52(11):1017&#x2013;1027. doi: 10.1007/s40262-013-0085-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-013-0085-2</ArticleId><ArticleId IdType="pmc">PMC3824374</ArticleId><ArticleId IdType="pubmed">23754736</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two Phase III trials. Ann Rheum Dis. 2022;81(7):951&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab Phase 2/3 trials. Ann Rheum Dis. 2022;81(7):962&#x2013;969. doi: 10.1136/annrheumdis-2021-221847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221847</ArticleId><ArticleId IdType="pmc">PMC9213793</ArticleId><ArticleId IdType="pubmed">35580976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716&#x2013;730. doi: 10.1038/nrrheum.2016.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2022;61(5):1900&#x2013;1910. doi: 10.1093/rheumatology/keab704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab704</ArticleId><ArticleId IdType="pmc">PMC9071514</ArticleId><ArticleId IdType="pubmed">34528084</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of Phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. doi: 10.1136/lupus-2020-000464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000464</ArticleId><ArticleId IdType="pmc">PMC7893670</ArticleId><ArticleId IdType="pubmed">33597205</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29(1):150&#x2013;164. doi: 10.1016/j.immuni.2008.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.05.012</ArticleId><ArticleId IdType="pmc">PMC2727981</ArticleId><ArticleId IdType="pubmed">18631455</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca. Saphnelo, INN-anifrolumab: summary of product characteristics. European Medicines Agency 2022 [cited April 13, 2022]; https://www.ema.europa.eu/en/documents/product-information/saphnelo-epar-product-information_en.pdf. Accessed 13 Apr 2022.</Citation></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Kalyani R, Abreu G, Pineda L, et al. Efficacy of anifrolumab in active systemic lupus erythematosus: patient subgroup analysis of BICLA response in 2 Phase 3 trials [Abstract OP0049] Ann Rheum Dis. 2020;79(Suppl 1):32. doi: 10.1136/annrheumdis-2020-eular.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-eular.3557</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535&#x2013;1543. doi: 10.2147/DDDT.S170969.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S170969</ArticleId><ArticleId IdType="pmc">PMC6514126</ArticleId><ArticleId IdType="pubmed">31190735</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Phase 3 study of anifrolumab in adult patients with active proliferative lupus nephritis (IRIS), NCT05138133. [cited September 22, 2022]; https://clinicaltrials.gov/ct2/show/NCT05138133.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Subcutaneous anifrolumab in adult patients with systemic lupus erythematosus (Tulip SC). [cited April 28, 2022]; https://clinicaltrials.gov/ct2/show/NCT04877691.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>